Columnist Jen Cueva has gotten more adept at listening to her body and making adjustments to manage her PH and leave room for joy.

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

Pulmonary hypertension (PH) risk grows over time for patients with narrowing of the aorta, the body's biggest blood vessel, ...

Boosting MTMR7 production reversed signs of pulmonary arterial hypertension in a mouse model of PAH and may serve as a ...

For columnist Anna Jeter, who's now post-transplant, protecting her health during the winter in Minnesota can be challenging ...

Tenax Therapeutics said it extended Phase 3 clinical development of PH treatment TNX-103, an oral form of levosimendan.

Insulin resistance correlates with disease severity in CTEPH, and an indicator may help predict clinical worsening in ...

Anna L. Jeter is an artist and writer living in Excelsior, Minnesota, with her parents and her sweet mini goldendoodle, Luna. Anna was diagnosed with pulmonary hypertension in 1999 at the age of 4.

Cuts to federal budgets have the rare disease community on edge. Columnist Jen Cueva calls on us to unite for our future.